Gamma knife surgery for intracranial cavernous hemangioma.
OBJECTIVE
The purpose of this study was to assess the benefits of radiosurgery for cavernous hemangioma.


METHODS
Sixty-five cavernous hemangiomas were treated with gamma knife surgery (GKS) between October 1994 and December 2002. Forty-two patients attended follow up. The mean patient age was 37.6 years (range 7-60 years). The lesions were located in the frontal lobe in 12 cases, deep in the parietal lobe in five, in the basal ganglia in five, in the temporal in three, in the cerebellum in three, in the pons/midbrain in six, and in multiple locations in eight cases. The presenting symptoms were seizure in 12, hemorrhage in 11, and other in 19. The maximum dose was 26.78 Gy, and the mean margin dose was 14.55 Gy. The mean follow-up period after radiosurgery was 29.6 months (range 5-93 months). The tumor decreased in size in 29 cases, was unchanged in 12, and increased in size in one. In the seizure group, seizures were controlled without anticonvulsant medication in nine cases (81.8%) after 31.3 months (range 12-80 months). After 93 months, one patient developed a cyst, which was resected. Rebleeding occurred in one case (2.3%). On T2-weighted imaging changes were seen in 11 cases (26.2%), in three (7.1 %) of which neurological deterioration was correlated with imaging changes. In other cases these deficits were temporary.


CONCLUSIONS
The authors found that GKS was an effective treatment modality for cavernous hemangiomas, especially for those located within the brainstem, basal ganglia, or deep portions of the brain. It can reduce seizure frequency significantly although this takes time. In the group receiving a marginal dose below 15 Gy the patients fared better than when the dose exceeded 15 Gy.
Kim
Moo Seong
MS
Department of Neurosurgery, University Busan Paik Hospital, Busan, South Korea. kinmmo@yahoo.co.kr
Pyo
Se Young
SY
Jeong
Young Gyun
YG
Lee
Sun Il
SI
Jung
Yong Tae
YT
Sim
Jae Hong
JH
D000293:Adolescent; D000328:Adult; D001479:Basal Ganglia / Q000473:pathology / Q000601:surgery; D001932:Brain Neoplasms / Q000150:complications / Q000473:pathology / Q000601:surgery*; D002531:Cerebellum / Q000473:pathology / Q000601:surgery; D002648:Child; D004569:Electroencephalography; D005500:Follow-Up Studies; D005625:Frontal Lobe / Q000473:pathology / Q000601:surgery; D020786:Hemangioma, Cavernous, Central Nervous System / Q000150:complications / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D010296:Parietal Lobe / Q000473:pathology / Q000601:surgery; D011149:Pons / Q000473:pathology / Q000601:surgery; D011829:Radiation Dosage; D016634:Radiosurgery / Q000295:instrumentation*; D012640:Seizures / Q000175:diagnosis / Q000209:etiology